Tricin‐Loaded Liposomes as a Passive Targeting Nanodelivery System for Enhanced Gastric Cancer Therapy
- 1School of Pharmacy, Health Science Center Xi'an Jiaotong University Xi'an P. R. China
- 2School of Pharmacy Jilin Medical University Jilin P. R. China
- 3Department of Pathology Jilin People's Hospital Jilin P. R. China
Abstract
Gastric cancer (GC) has a poor prognosis. Chemotherapy causes severe systemic toxicity, and only a small subset of patients benefits from HER2/PD‑L1‑targeted therapies. Tricin (TRI), a natural flavonoid with anti‑GC activity, is limited by poor water solubility and low bioavailability. This study aimed to construct TRI‑loaded liposomes (TRI@Lips) to overcome these drawbacks and evaluate their antitumor performance. TRI@Lips were prepared by thin‑film hydration and characterized by DLS, FTIR, TEM, and release assays. Cytotoxicity, cellular uptake, in vivo tumor distribution, antitumor efficacy, and biosafety were examined using SGC‑7901/GSE‑1 cells, fluorescent tracers, and xenograft mice. TRI@Lips showed uniform spherical morphology (average size: 217.5 nm, PDI: 0.198, zeta potential: −8.84 mV), with 87.3% encapsulation efficiency, 9.2% drug loading, and 67.2% release at pH 5.0 within 72 h. The IC50 against SGC‑7901 cells was 3.4 µg/mL, with minimal toxicity to GSE‑1 cells. EPR‑mediated tumor accumulation was confirmed. In vivo, TRI@Lips reduced tumor weight to 0.3 g and Ki67‑positive rate to 11.6%, without major organ injury. TRI@Lips enhance TRI solubility, cellular uptake, and tumor accumulation, representing a low‑toxic passive‑targeting candidate for GC treatment.
Related
- pH-Responsive Erdafitinib Liposomes with FGFR3 Targeting for Intravesical Bladder Cancer Therapy
- Targeting the Helicobacter pylori–Gastric Cancer Axis with Nanomaterials: From Infection Control to Tumor-Directed Therapy
- Innovative hyaluronic acid-decorated quatsomes for enhanced renal targeting: design, optimization and in-vivo biochemical and nephroprotective assessments
- In vitro and in vivo evaluation of liposomes constructed with Rg3 as a cholesterol substitute for tumor therapy
- Effect of Glucose and Methyl Glucoside on the Structure and Physicochemical Properties of Liposomes
BibTeX
@article{cui2026tricinloaded,
title = {{Tricin‐Loaded Liposomes as a Passive Targeting Nanodelivery System for Enhanced Gastric Cancer Therapy}},
author = {Baiji Cui and Hongmei Zhang and Hao Wu and Libo Wang and Tianyi Zhang and Zengjun Guo},
journal = {Chemistry \& Biodiversity},
year = {2026},
month = oct,
doi = {10.1002/cbdv.71830},
url = {https://doi.org/10.1002/cbdv.71830},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Tricin‐Loaded Liposomes as a Passive Targeting Nanodelivery System for Enhanced Gastric Cancer Therapy
AU - Baiji Cui
AU - Hongmei Zhang
AU - Hao Wu
AU - Libo Wang
AU - Tianyi Zhang
AU - Zengjun Guo
PY - 2026
DA - 2026/10/27
JO - Chemistry & Biodiversity
DO - 10.1002/cbdv.71830
UR - https://doi.org/10.1002/cbdv.71830
AB - Gastric cancer (GC) has a poor prognosis. Chemotherapy causes severe systemic toxicity, and only a small subset of patients benefits from HER2/PD‑L1‑targeted therapies. Tricin (TRI), a natural flavonoid with anti‑GC activity, is limited by poor water solubility and low bioavailability. This study aimed to construct TRI‑loaded liposomes (TRI@Lips) to overcome these drawbacks and evaluate their antitumor performance. TRI@Lips were prepared by thin‑film hydration and characterized by DLS, FTIR, TEM, and release assays. Cytotoxicity, cellular uptake, in vivo tumor distribution, antitumor efficacy, and biosafety were examined using SGC‑7901/GSE‑1 cells, fluorescent tracers, and xenograft mice. TRI@Lips showed uniform spherical morphology (average size: 217.5 nm, PDI: 0.198, zeta potential: −8.84 mV), with 87.3% encapsulation efficiency, 9.2% drug loading, and 67.2% release at pH 5.0 within 72 h. The IC50 against SGC‑7901 cells was 3.4 µg/mL, with minimal toxicity to GSE‑1 cells. EPR‑mediated tumor accumulation was confirmed. In vivo, TRI@Lips reduced tumor weight to 0.3 g and Ki67‑positive rate to 11.6%, without major organ injury. TRI@Lips enhance TRI solubility, cellular uptake, and tumor accumulation, representing a low‑toxic passive‑targeting candidate for GC treatment.
SN - 1612-1872
SN - 1612-1880
ER -